JB Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$339K Sell
5,588
-28
-0.5% -$1.63K 0.01% 205
2025
Q4
$303K Hold
5,616
0.01% 212
2025
Q3
$253K Buy
5,616
+37
+0.7% +$1.73K 0.01% 221
2025
Q2
$258K Buy
5,579
+393
+8% +$19.3K 0.01% 214
2025
Q1
$316K Sell
5,186
-479
-8% -$27.9K 0.02% 180
2024
Q4
$320K Sell
5,665
-29
-0.5% -$1.62K 0.02% 178
2024
Q3
$295K Sell
5,694
-6
-0.1% -$281 0.02% 183
2024
Q2
$237K Sell
5,700
-40
-0.7% -$1.79K 0.01% 208
2024
Q1
$311K Sell
5,740
-1,165
-17% -$59.3K 0.02% 180
2023
Q4
$354K Buy
6,905
+140
+2% +$7.35K 0.03% 158
2023
Q3
$393K Sell
6,765
-115
-2% -$7.05K 0.03% 129
2023
Q2
$440K Sell
6,880
-77
-1% -$5.16K 0.04% 116
2023
Q1
$482K Buy
6,957
+434
+7% +$30.6K 0.04% 110
2022
Q4
$469K Buy
6,523
+29
+0.4% +$2.19K 0.05% 109
2022
Q3
$462K Sell
6,494
-258
-4% -$18.7K 0.05% 105
2022
Q2
$520K Buy
6,752
+27
+0.4% +$2.06K 0.06% 152
2022
Q1
$492K Buy
6,725
+351
+6% +$23.6K 0.05% 167
2021
Q4
$397K Sell
6,374
-302
-5% -$17.7K 0.04% 183
2021
Q3
$395K Buy
+6,676
New +$440K 0.05% 189

Other funds holding BMY

JB Capital's BMY Position: Q1 2026 in Review

JB Capital reduced its Bristol-Myers Squibb (BMY) stake by 0.5% in Q1 2026, selling an estimated $1.63K and leaving 5,588 shares worth $339K. The position accounts for 0.01% of the portfolio, ranked #205.

JB Capital first reported a position in BMY in Q3 2021 and has held it in 19 quarters since. The position peaked at $520K in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • JB Capital held 5,588 shares of Bristol-Myers Squibb worth $339K as of Q1 2026.
  • JB Capital sold 28 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.63K.
  • Bristol-Myers Squibb made up 0.01% of JB Capital's portfolio in Q1 2026, its #205 holding.
  • JB Capital first reported a position in Bristol-Myers Squibb in Q3 2021 and has held it in 19 quarters since.
  • JB Capital's Bristol-Myers Squibb position peaked at $520K in Q2 2022.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on JB Capital's 13F filing for Q1 2026, filed 27 Apr 2026.